Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy (Q33390778)

26 July 2017

title

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy (English)

1 reference

26 July 2017

1 reference

myelodysplastic syndrome

1 reference

Hagop M Kantarjian

1 reference

26 July 2017

Guillermo Garcia-Manero

object named as

Guillermo Garcia-Manero

1 reference

26 July 2017

Francis J Giles

1 reference

26 July 2017

Everett Peter Greenberg

object named as

Peter L Greenberg

1 reference

26 July 2017

Ron L Paquette

1 reference

26 July 2017

Eunice S Wang

1 reference

26 July 2017

Janice L Gabrilove

1 reference

26 July 2017

Kuolung Hu

1 reference

26 July 2017

Janet L Franklin

1 reference

26 July 2017

Dietmar P Berger

1 reference

26 July 2017

language of work or name

English

0 references

publication date

14 July 2010

1 reference

26 July 2017

1 reference

inferred from page(s)

published in

Blood

1 reference

26 July 2017

volume

116

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

3163-3170

1 reference

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

How I treat patients with myelodysplastic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Myelodysplastic syndrome: an update on diagnosis and therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Myelodysplastic syndromes: molecular pathogenesis and genomic changes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Risk-based management of myelodysplastic syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

New approaches to the treatment of myelodysplasia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Non-infectious complications of transfusion therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

International scoring system for evaluating prognosis in myelodysplastic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324162

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20631375

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20631375

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2010-03-274753

1 reference

26 July 2017

1 reference

26 July 2017

1 reference